Trafficking through the Rev/RRE pathway is essential for efficient inhibition of human immunodeficiency virus type 1 by an antisense RNA derived from the envelope gene

Journal of Virology

Volumn 83, Issue 2, 2009, Pages 940-952

  Ward, Alex M ^a   Rekosh, David ^a   Hammarskjold, Marie Louise ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; COMPLEMENTARY RNA; MESSENGER RNA; VIRUS VECTOR;

ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; GENE CONSTRUCT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; MASON PFIZER MONKEY VIRUS; PLASMID; POLYSOME; PRIORITY JOURNAL; RNA DEGRADATION; VIRUS ENVELOPE; VIRUS EXPRESSION; VIRUS INHIBITION;

ANTI-HIV AGENTS; CELL LINE; GENES, ENV; HIV-1; HUMANS; RNA TRANSPORT; RNA, ANTISENSE; VIRAL PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS 1; MASON-PFIZER MONKEY VIRUS;

EID: 58149487625     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01520-08     Document Type: Article

References (79)

1. Bass, B. L. 2002. RNA editing by adenosine deaminases that act on RNA. Annu. Rev. Biochem. 71:817-846.
2. Boden, D., O. Pusch, F. Lee, L. Tucker, and B. Ramratnam. 2003. Human immunodeficiency virus type 1 escape from RNA interference. J. Virol. 77:11531-11535.
3. Bor, Y. C., J. Swartz, A. Morrison, D. Rekosh, M. Ladomery, and M. L. Hammarskjold. 2006. The Wilms' tumor 1 (WT1) gene (+KTS isoform) functions with a CTE to enhance translation from an unspliced RNA with a retained intron. Genes Dev. 20:1597-1608.
4. Bray, M., S. Prasad, J. W. Dubay, E. Hunter, K. T. Jeang, D. Rekosh, and M. L. Hammarskjold. 1994. A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent. Proc. Natl. Acad. Sci. USA 91:1256-1260.
5. Briquet, S., J. Richardson, C. Vanhee-Brossollet, and C. Vaquero. 2001. Natural antisense transcripts are detected in different cell lines and tissues of cats infected with feline immunodeficiency virus. Gene 267:157-164.
6. Calzone, F. J., R. C. Angerer, and M. A. Gorovsky. 1982. Regulation of protein synthesis in Tetrahymena: isolation and characterization of polysomes by gel filtration and precipitation at pH 5.3. Nucleic Acids Res. 10:2145-2161.
7. Cavanagh, M. H., S. Landry, B. Audet, C. Arpin-Andre, P. Hivin, M. E. Pare, J. Thete, E. Wattel, S. J. Marriott, J. M. Mesnard, and B. Barbeau. 2006. HTLV-1 antisense transcripts initiating in the 3′LTR are alternatively spliced and polyadenylated. Retrovirology 3:15.
8. Chang, D. D., and P. A. Sharp. 1989. Regulation by HIV Rev depends upon recognition of splice sites. Cell 59:789-795.
9. Chen, J., M. Sun, W. J. Kent, X. Huang, H. Xie, W. Wang, G. Zhou, R. Z. Shi, and J. D. Rowley. 2004. Over 20% of human transcripts might form sense-antisense pairs. Nucleic Acids Res. 32:4812-4820.
10. Chu, C. Y., and T. M. Rana. 2006. Translation repression in human cells by microRNA-induced gene silencing requires RCK/p54. PLoS Biol. 4:e210.
11. Crooke, S. T. 2004. Progress in antisense technology. Annu. Rev. Med. 55:61-95.
12. Elbashir, S. M., J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, and T. Tuschl. 2001. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494-498.
13. Ernst, R. K., M. Bray, D. Rekosh, and M. L. Hammarskjold. 1997. A structured retroviral RNA element that mediates nucleocytoplasmic export of intron-containing RNA. Mol. Cell. Biol. 17:135-144.
14. Felber, B. K., M. Hadzopoulou-Cladaras, C. Cladaras, T. Copeland, and G. N. Pavlakis. 1989. rev protein of human immunodeficiency virus type 1 affects the stability and transport of the viral mRNA. Proc. Natl. Acad. Sci. USA 86:1495-1499.
15. Fornerod, M., M. Ohno, M. Yoshida, and I. W. Mattaj. 1997. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 90:1051-1060.
16. Frankel, A. D., and J. A. Young. 1998. HIV-1: fifteen proteins and an RNA. Annu. Rev. Biochem. 67:1-25.
17. Ge, X., W. S. Rubinstein, Y. C. Jung, and Q. Wu. 2008. Genome-wide analysis of antisense transcription with Affymetrix exon array. BMC Genomics 9:27.
18. Giordano, V., D. Y. Jin, D. Rekosh, and K. T. Jeang. 2000. Intravirion targeting of a functional anti-human immunodeficiency virus ribozyme directed to pol. Virology 267:174-184.
19. Graham, F. L., and A. J. van der Eb. 1973. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52:456-467.
20. Gruter, P., C. Tabernero, C. von Kobbe, C. Schmitt, C. Saavedra, A. Bachi, M. Wilm, B. K. Felber, and E. Izaurralde. 1998. TAP, the human homolog of Mex67p, mediates CTE-dependent RNA export from the nucleus. Mol. Cell 1:649-659.
21. Guzik, B. W., L. Levesque, S. Prasad, Y. C. Bor, B. E. Black, B. M. Paschal, D. Rekosh, and M. L. Hammarskjold. 2001. NXT1 (p15) is a crucial cellular cofactor in TAP-dependent export of intron-containing RNA in mammalian cells. Mol. Cell. Biol. 21:2545-2554.
22. Hammarskjold, M. L. 1997. Regulation of retroviral RNA export. Semin. Cell Dev. Biol. 8:83-90.
23. Hammarskjold, M. L., J. Heimer, B. Hammarskjold, I. Sangwan, L. Albert, and D. Rekosh. 1989. Regulation of human immunodeficiency virus env expression by the rev gene product. J. Virol. 63:1959-1966.
24. Hammarskjold, M. L., H. Li, D. Rekosh, and S. Prasad. 1994. Human immunodeficiency virus env expression becomes Rev-independent if the env region is not defined as an intron. J. Virol. 68:951-958.
25. Hatzoglou, A., F. Deshayes, C. Madry, G. Lapree, E. Castanas, and A. Tsapis. 2002. Natural antisense RNA inhibits the expression of BCMA, a tumour necrosis factor receptor homologue. BMC Mol. Biol. 3:4.
26. Heidenreich, O., S. H. Kang, X. Xu, and M. Nerenberg. 1995. Application of antisense technology to therapeutics. Mol. Med. Today 1:128-133.
27. Hope, T. J. 1999. The ins and outs of HIV Rev. Arch. Biochem. Biophys. 365:186-191.
28. Hope, T. J., D. McDonald, X. J. Huang, J. Low, and T. G. Parslow. 1990. Mutational analysis of the human immunodeficiency virus type 1 Rev transactivator: essential residues near the amino terminus. J. Virol. 64:5360-5366.
29. Hovanessian, A. G. 2007. On the discovery of interferon-inducible, double-stranded RNA activated enzymes: the 2-5oligoadenylate synthetases and the protein kinase PKR. Cytokine Growth Factor Rev. 18:351-361.
30. Jin, L., B. W. Guzik, Y. C. Bor, D. Rekosh, and M. L. Hammarskjold. 2003. Tap and NXT promote translation of unspliced mRNA. Genes Dev. 17: 3075-3086.
31. Johannes, G., and P. Sarnow. 1998. Cap-independent polysomal association of natural mRNAs encoding c-myc, BiP, and eIF4G conferred by internal ribosome entry sites. RNA 4:1500-1513.
32. Kim, K., and F. Liu. 2007. Inhibition of gene expression in human cells using RNase P-derived ribozymes and external guide sequences. Biochim. Biophys. Acta 1769:603-612.
33. Kjems, J., M. Brown, D. D. Chang, and P. A. Sharp. 1991. Structural analysis of the interaction between the human immunodeficiency virus Rev protein and the Rev response element. Proc. Natl. Acad. Sci. USA 88:683-687.
34. Konstantinova, P., W. de Vries, J. Haasnoot, O. ter Brake, P. de Haan, and B. Berkhout. 2006. Inhibition of human immunodeficiency virus type 1 by RNA interference using long-hairpin RNA. Gene Ther. 13:1403-1413.
35. Kuersten, S., S. P. Segal, J. Verheyden, S. M. LaMartina, and E. B. Goodwin. 2004. NXF-2, REF-1, and REF-2 affect the choice of nuclear export pathway for tra-2 mRNA in Caenorhabditis elegans. Mol. Cell 14:599-610.
36. Kumar, M., and G. G. Carmichael. 1997. Nuclear antisense RNA induces extensive adenosine modifications and nuclear retention of target transcripts. Proc. Natl. Acad. Sci. USA 94:3542-3547.
37. Landry, S., M. Halin, S. Lefort, B. Audet, C. Vaquero, J. M. Mesnard, and B. Barbeau. 2007. Detection, characterization and regulation of antisense transcripts in HIV-1. Retrovirology 4:71.
38. Lehmann, M. J., V. Patzel, and G. Sczakiel. 2000. Theoretical design of antisense genes with statistically increased efficacy. Nucleic Acids Res. 28:2597-2604.
39. Levine, B. L., L. M. Humeau, J. Boyer, R. R. MacGregor, T. Rebello, X. Lu, G. K. Binder, V. Slepushkin, F. Lemiale, J. R. Mascola, F. D. Bushman, B. Dropulic, and C. H. June. 2006. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc. Natl. Acad. Sci. USA 103:17372-17377.
40. Lim, S. K., C. D. Sigmund, K. W. Gross, and L. E. Maquat. 1992. Nonsense codons in human beta-globin mRNA result in the production of mRNA degradation products. Mol. Cell. Biol. 12:1149-1161.
41. Liu, J., M. A. Carmell, F. V. Rivas, C. G. Marsden, J. M. Thomson, J. J. Song, S. M. Hammond, L. Joshua-Tor, and G. J. Hannon. 2004. Argonaute2 is the catalytic engine of mammalian RNAi. Science 305:1437-1441.
42. Lu, X., Q. Yu, G. K. Binder, Z. Chen, T. Slepushkina, J. Rossi, and B. Dropulic. 2004. Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistance. J. Virol. 78:7079-7088.
43. - T lymphocytes of non-infected donors contain cytotoxic T lymphocyte precursors at high frequency. Int. Immunol. 6:1739-1749.
44. Luciw, P. 1996. Human immunodeficiency viruses and their replication, 3rd ed., vol. 2. Lippincott-Raven, Philadelphia, PA.
45. Ludwig, L. B., J. L. Ambrus, Jr., K. A. Krawczyk, S. Sharma, S. Brooks, C. B. Hsiao, and S. A. Schwartz. 2006. Human immunodeficiency virus type 1 LTR DNA contains an intrinsic gene producing antisense RNA and protein products. Retrovirology 3:80.
46. Malim, M. H., S. Bohnlein, J. Hauber, and B. R. Cullen. 1989. Functional dissection of the HIV-1 Rev transactivator: derivation of a trans-dominant repressor of Rev function. Cell 58:205-214.
47. Malim, M. H., J. Hauber, S. Y. Le, J. V. Maizel, and B. R. Cullen. 1989. The HIV-1 rev transactivator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 338:254-257.
48. Maroney, P. A., Y. Yu, J. Fisher, and T. W. Nilsen. 2006. Evidence that microRNAs are associated with translating messenger RNAs in human cells. Nat. Struct. Mol. Biol. 13:1102-1107.
49. Martinez-Cajas, J. L., and M. A. Wainberg. 2008. Antiretroviral therapy: optimal sequencing of therapy to avoid resistance. Drugs 68:43-72.
50. Michael, N. L., M. T. Vahey, L. d'Arcy, P. K. Ehrenberg, J. D. Mosca, J. Rappaport, and R. R. Redfield. 1994. Negative-strand RNA transcripts are produced in human immunodeficiency virus type 1-infected cells and patients by a novel promoter downregulated by Tat. J. Virol. 68:979-987.
51. Nottrott, S., M. J. Simard, and J. D. Richter. 2006. Human let-7a miRNA blocks protein production on actively translating polyribosomes. Nat. Struct. Mol. Biol. 13:1108-1114.
52. Ohman, M. 2007. A-to-I editing challenger or ally to the microRNA process. Biochimie 89:1171-1176.
53. Otero, G. C., M. E. Harris, J. E. Donello, and T. J. Hope. 1998. Leptomycin B inhibits equine infectious anemia virus Rev and feline immunodeficiency virus rev function but not the function of the hepatitis B virus posttranscriptional regulatory element. J. Virol. 72:7593-7597.
54. Park, J., and C. D. Morrow. 1992. The nonmyristylated Pr160gag-pol polyprotein of human immunodeficiency virus type 1 interacts with Pr55gag and is incorporated into viruslike particles. J. Virol. 66:6304-6313.
55. Parker, R., and U. Sheth. 2007. P bodies and the control of mRNA translation and degradation. Mol. Cell 25:635-646.
56. Piacenti, F. J. 2006. An update and review of antiretroviral therapy. Pharmacotherapy 26:1111-1133.
57. Prasanth, K. V., S. G. Prasanth, Z. Xuan, S. Hearn, S. M. Freier, C. F. Bennett, M. Q. Zhang, and D. L. Spector. 2005. Regulating gene expression through RNA nuclear retention. Cell 123:249-263.
58. Purcell, D. F., and M. A. Martin. 1993. Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. J. Virol. 67:6365-6378.
59. Ramezani, A., X. Z. Ma, R. Nazari, and S. Joshi. 2002. Development and testing of retroviral vectors expressing multimeric hammerhead ribozymes targeted against all major clades of HIV-1. Front. Biosci. 7:a29-a36.
60. Rittner, K., and G. Sczakiel. 1991. Identification and analysis of antisense RNA target regions of the human immunodeficiency virus type 1. Nucleic Acids Res. 19:1421-1426.
61. Rossi, J. J., C. H. June, and D. B. Kohn. 2007. Genetic therapies against HIV. Nat. Biotechnol. 25:1444-1454.
62. Satou, Y., J. Yasunaga, M. Yoshida, and M. Matsuoka. 2006. HTLV-1 basic leucine zipper factor gene mRNA supports proliferation of adult T-cell leukemia cells. Proc. Natl. Acad. Sci. USA 103:720-725.
63. Scherer, L., J. J. Rossi, and M. S. Weinberg. 2007. Progress and prospects: RNA-based therapies for treatment of HIV infection. Gene Ther. 14:1057-1064.
64. Scherer, L. J., and J. J. Rossi. 2003. Approaches for the sequence-specific knockdown of mRNA. Nat. Biotechnol. 21:1457-1465.
65. Schutz, S., J. Chemnitz, C. Spillner, M. Frohme, J. Hauber, and R. H. Kehlenbach. 2006. Stimulated expression of mRNAs in activated T cells depends on a functional CRM1 nuclear export pathway. J. Mol. Biol. 358:997-1009.
66. Senserrich, J., E. Pauls, M. Armand-Ugon, I. Clotet-Codina, G. Moncunill, B. Clotet, and J. A. Este. 2008. HIV-1 resistance to the anti-HIV activity of a shRNA targeting a dual-coding region. Virology 372:421-429.
67. Seraphin, B., and M. Rosbash. 1989. Identification of functional U1 snRNA-pre-mRNA complexes committed to spliceosome assembly and splicing. Cell 59:349-358.
68. Sivan, G., N. Kedersha, and O. Elroy-Stein. 2007. Ribosomal slowdown mediates translational arrest during cellular division. Mol. Cell. Biol. 27:6639-6646.
69. Smith, A. J., N. Srinivasakumar, M. L. Hammarskjold, and D. Rekosh. 1993. Requirements for incorporation of Pr160gag-pol from human immunodeficiency virus type 1 into virus-like particles. J. Virol. 67:2266-2275.
70. Thermann, R., and M. W. Hentze. 2007. Drosophila miR2 induces pseudopolysomes and inhibits translation initiation. Nature 447:875-878.
71. Usui, T., K. Yanagihara, K. Tsukasaki, K. Murata, H. Hasegawa, Y. Yamada, and S. Kamihira. 2008. Characteristic expression of HTLV-1 basic zipper factor (HBZ) transcripts in HTLV-1 provirus-positive cells. Retrovirology 5:34.
72. Ventura, M., P. Wang, N. Franck, and S. Saragosti. 1994. Ribozyme targeting of HIV-1 LTR. Biochem. Biophys. Res. Commun. 203:889-898.
73. Wehrly, K., and B. Chesebro. 1997. p24 antigen capture assay for quantification of human immunodeficiency virus using readily available inexpensive reagents. Methods 12:288-293.
74. Wolff, B., J. J. Sanglier, and Y. Wang. 1997. Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA. Chem. Biol. 4:139-147.
75. Wu, L., J. Fan, and J. G. Belasco. 2006. MicroRNAs direct rapid deadenylation of mRNA. Proc. Natl. Acad. Sci. USA 103:4034-4039.
76. Wyszko, E., M. Z. Barciszewska, R. Bald, V. A. Erdmann, and J. Barciszewski. 2001. The specific hydrolysis of HIV-1 TAR RNA element with the anti-TAR hammerhead ribozyme: structural and functional implications. Int. J. Biol. Macromol. 28:373-380.
77. Zhang, J., X. Sun, Y. Qian, and L. E. Maquat. 1998. Intron function in the nonsense-mediated decay of beta-globin mRNA: indications that pre-mRNA splicing in the nucleus can influence mRNA translation in the cytoplasm. RNA. 4:801-815.
78. Zhang, Z., and G. G. Carmichael. 2001. The fate of dsRNA in the nucleus: a p54(nrb)-containing complex mediates the nuclear retention of promiscuously A-to-I edited RNAs. Cell 106:465-475.
79. Zolotukhin, A. S., A. Valentin, G. N. Pavlakis, and B. K. Felber. 1994. Continuous propagation of RRE(-) and Rev(-) RRE(-) human immunodeficiency virus type 1 molecular clones containing a cis-acting element of simian retrovirus type 1 in human peripheral blood lymphocytes. J. Virol. 68:7944-7952.